Fulvestrant: A review of its development, pre-clinical and clinical data

International Journal of Clinical Practice

Volumn 56, Issue 4, 2002, Pages 305-309

  Wardley, A M ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; FULVESTRANT; GEFITINIB; HORMONE RECEPTOR; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER RESISTANCE; CANCER STAGING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG STRUCTURE; ENDOMETRIUM; ESTROGEN ACTIVITY; FEMALE; GASTROINTESTINAL SYMPTOM; HORMONAL THERAPY; HOT FLUSH; HUMAN; INJECTION SITE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; RETROSPECTIVE STUDY; THROMBOEMBOLISM; URINARY TRACT INFECTION;

ANIMALS; BONE DENSITY; BREAST NEOPLASMS; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MICE; MICE, NUDE; MODELS, ANIMAL; OVARY; RANDOMIZED CONTROLLED TRIALS; STEROIDS; UTERUS;

EID: 0036279159     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. The pharmacology and clinical uses of tamoxifen
2. Tamoxifen and the uterus
3. Gynecologic effects of tamoxifen and the association with endometrial carcinoma
4. Acquired tamoxifen resistance: Correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen
5. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration
6. Tamoxifen therapy in premenopausal patients with metastatic breast cancer
7. Combined modality therapy for first recurrence of breast cancer: A Southwest Oncology Group study
8. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth
9. Response after withdrawal of tamoxifen and progestogens in advanced breast cancer
10. Steroidal pure antioestrogens
11. Biology and mode of action of pure antioestrogens
12. Novel steroidal pure antiestrogens
13. A potent specific pure antiestrogen with clinical potential
14. Action of 'pure' antiestrogens in inhibiting estrogen receptor action
15. The future of new pure antiestrogens in clinical breast cancer
16. Gene regulation by steroid hormones
17. Basic guide to the mechanisms of antiestrogen action
18. Nuclear receptor coactivators and corepressors
19. Molecular basis of agonism and antagonism in the oestrogen receptor
20. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions
21. Tripartite steroid hormone receptor pharmacology: Interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones
22. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer
23. Use of pure antioestrogens to elucidate the mode of action of oestrogens
24. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling
25. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines
26. Inhibition of estrogen receptor-DNA binding by the 'pure' antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization
27. Effect of antagonists on DNA-binding properties of the human estrogen receptor in vitro and in vivo
28. The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue
29. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover
30. The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity
31. Antiuterotrophic effects of a pure antioestrogen, ICI 182,780: Magnetic resonance imaging of the uterus in ovariectomized monkeys
32. Antiuterotrophic effects of the pure antioestrogen ICI 182,780 in adult female monkeys (Macaca nemestrina): Quantitative magnetic resonance imaging
33. Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer
34. The effects of ICI 182,780, a pure anti-oestrogen, on the hypothalamic-pituitary-gonadal axis and on endometrial proliferation in pre-menopausal women
35. Effects of the pure anti-oestrogen ICI 182780 on oestrogen receptors, progesterone receptors and Ki67 antigen in human endometrium in vivo
36. Actions of oestrogens and antioestrogens on rat mammary gland development: Relevance to breast cancer prevention
37. Novel antioestrogens without partial agonist activity
38. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer
39. Long-term adjuvant therapy with tamoxifen: Effects on sex hormone binding globulin and antithrombin III
40. Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy
41. 17 beta-estradiol increases calcium content in fetal mouse parietal bones cultured in serum-free medium only at physiological concentrations
42. The estrogen antagonist ICI 182,780 reduces cancellous bone volume in female rats
43. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1
44. Activity of tamoxifen and new antiestrogens on estrogen receptor positive and negative breast cancer cells
45. Comparison between novel steroid-like and conventional nonsteroidal antioestrogens in inhibiting oestradiol- and IGF-I-induced proliferation of human breast cancer-derived cells
46. Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment
47. Effects of antioestrogens on the proliferation of MCF-7 human breast cancer cells
48. Regulation of insulin-like growth factor I receptor expression by the pure antiestrogen ICI 182780
49. Comparative studies on the effects of steroidal and nonsteroidal oestrogen antagonists on the proliferation of human breast cancer cells
50. Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells
51. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice
52. The Pharmacokinetics of single dose Faslodex™ (ICI 182,780) in postmenopausal primary breast cancer: Relationship with estrogen receptor (ER) down regulation
53. ICI 182,780 (Faslodex) 250 mg monthly intramuscular injection shows consistent PK during long-term dosing in post-menopausal women with advanced breast cancer
54. Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer
55. Models of new antioestrogen activity in vivo: Primary tumours
56. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells
57. Effect of N-(4-hydroxyphenyl)retinamide on apoptosis in human breast cancer cells
58. Estrogen control of progesterone receptor in human breast cancer: Role of estradiol and antiestrogen
59. Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7
60. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer
61. Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer
62. Modulation of estrogen receptor and epidermal growth factor receptor mRNAs by phorbol ester in MCF 7 breast cancer cells
63. Effect of sodium butyrate on estrogen receptor and epidermal growth factor receptor gene expression in human breast cancer cell lines
64. The EGFR-selective tyrosine kinase inhibitor ZD1839 (Iressa) is an effective inhibitor of tamoxifen-resistant breast cancer growth
65. CI 182,780 (Faslodex™) versus anastrozole (Arimidex™) for the treatment of advanced breast cancer in postmenopausal women: Prospective combined analysis of two multicenter trials
66. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in post-menopausal women: Results of a North American multicenter randomized trial
67. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study
68. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials
69. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate
70. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group